P. Tomczak

发表

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

David McDermott, R. Figlin, R. Motzer, 2007, The New England journal of medicine.

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

A. Santoro, M. Inbar, L. Alland, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study

R. Motzer, C. Sternberg, P. Tomczak, 2018, European journal of cancer.

Anthracycline-induced cardiomyopathy, an essential diagnostic and therapeutic problem in oncological practice

P. Tomczak, E. Bręborowicz, P. Bręborowicz, 2007 .

AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): A randomized, double-blind, placebo-controlled, phase II study.

B. Rini, C. Szczylik, B. Escudier, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

S. Culine, J. Hainsworth, R. Huddart, 2017, The Lancet.

Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.

J. Patard, A. Ravaud, R. Motzer, 2018, European urology.

Systemic treatment of patients with solid tumors during the COVID-19 (SARS-CoV-2) pandemic — comprehensive recommendations of the Polish Society of Clinical Oncology

M. Krzakowski, P. Tomczak, M. Wojtukiewicz, 2020, Oncology in Clinical Practice.

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

D. Miles, L. Dirix, G. Romieu, 2013, British Journal of Cancer.

Erratum: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial (Lancet (2011) 378 (1931-39))

B. Rini, B. Escudier, P. Tomczak, 2012 .

Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study.

A. Ravaud, T. Choueiri, M. Atkins, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)

R. Figlin, R. Motzer, M. Michaelson, 2008 .

A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)

D. Amadori, M. Moroni, N. Ibrahim, 2021, Breast Cancer Research and Treatment.

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

J. Burke, T. Powles, T. Choueiri, 2021, The New England journal of medicine.

A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC).

R. Figlin, M. Carducci, G. Hudes, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-{alpha}) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC)

R. Figlin, R. Motzer, M. Michaelson, 2006 .

Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC).

R. Figlin, R. Motzer, M. Michaelson, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

R. Motzer, M. Gore, R. Motzer, 2011, The Lancet.

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.

T. Powles, T. Choueiri, S. Park, 2021 .

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

Arlene Chan, Andreas Schneeweiss, Luc Y Dirix, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ZALECENIA POSTĘPOWANIA DIAGNOSTYCZNO-TERAPEUTYCZNEGO W RAKU NERKOWOKOMÓRKOWYM

M. Krzakowski, P. Tomczak, P. Wysocki, 2021, Oncology in Clinical Practice.

GUIDELINES FOR DIAGNOSTIC AND THERAPEUTIC MANAGEMENT Polish Society of Clinical Oncology and Polish Urological Association Guidelines for the diagnosis and treatment of renal cell cancer

M. Krzakowski, P. Tomczak, P. Wysocki, 2021 .

Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial.

R. Motzer, A. Berkenblit, C. Sternberg, 2012 .

Nivolumab in the treatment of advanced renal cell carcinoma

P. Tomczak, Zuzanna Synowiec, 2019, Oncology in Clinical Practice.

Demonstration of Clinical Comparability of the Biosimilar Filgrastim to Neupogen, in Terms of Safety and Efficacy, in Healthy Volunteers and Patients Receiving Myelosuppressive Chemotherapy

H. Gadgil, P. Tomczak, B. Jilma, 2014 .

Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial.

R. Motzer, B. Rini, C. Szczylik, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adenocarcinoma of the appendix — case study

R. Ramlau, P. Tomczak, Olga Milbrandt, 2017 .

AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney

A. Ravaud, M. Fishman, R. Ramlau, 2012, Cancer.

4509 POSTER Sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors

R. Figlin, R. Motzer, M. Michaelson, 2007 .

Phase II study of BAY 73-4506, a multikinase inhibitor, in previously untreated patients with metastatic or unresectable renal cell cancer.

T. Eisen, H. Joensuu, P. Nathan, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

Xin Huang, Roberto Pili, R. Figlin, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B.

M. Atkins, V. Matveev, F. Pouliot, 2019, Journal of Clinical Oncology.

The susceptibility to amphotericin B-induced hemolysis of erythrocytes from women with breast cancer before and during therapy

Z. Kopczyński, P. Tomczak, R. Gryczka, 2006, Comparative Clinical Pathology.

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

R. Figlin, R. Motzer, M. Michaelson, 2007, The New England journal of medicine.

Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.

R. Motzer, D. Cella, A. Berkenblit, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.

R. Motzer, M. Gore, M. Michaelson, 2013, The Lancet. Oncology.

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Fernando Maciel Barbosa, Raymond J. McDermott, J. Burke, 2022, The Lancet. Oncology.

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

J. Patard, A. Ravaud, R. Motzer, 2016, The New England journal of medicine.

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma

M. Atkins, V. Matveev, F. Pouliot, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non‒clear cell renal cell carcinoma (NCC-RCC).

M. Climent, M. Atkins, V. Matveev, 2019, Journal of Clinical Oncology.

Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

R. Amato, C. Szczylik, P. Tomczak, 2010, Clinical Cancer Research.

Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.

N. Harbeck, D. Miles, L. Dirix, 2008 .

Axitinib Trough Concentration and its Influence on the Efficacy and Toxicity of Second-line Renal Cell Carcinoma Treatment.

A. Jabłecka, P. Tomczak, A. Tężyk, 2022, Clinical genitourinary cancer.

Real-world Experience of Cabozantinib as Second- or Subsequent Line Treatment in Patients With Metastatic Renal Cell Carcinoma: Data From the Polish Managed Access Program.

L. Bodnar, P. Tomczak, A. Kopczyńska, 2019, Clinical genitourinary cancer.

Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1.

V. Velcheti, M. Ernstoff, K. Lewis, 2022, Journal of Clinical Oncology.

Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.

R. Motzer, T. Powles, T. Choueiri, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564.

T. Powles, T. Choueiri, S. Park, 2022, Journal of Clinical Oncology.

Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial.

Michael Jeffers, Heikki Joensuu, Tim Eisen, 2012, The Lancet. Oncology.

Significance of BRCA1 expression in breast and ovarian cancer patients with brain metastasis - A multicentre study.

R. Ramlau, R. Jach, W. Bednarek, 2019, Advances in medical sciences.

Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.

J. Larkin, M. Atkins, V. Matveev, 2018 .

7103 ORAL Association of Single Nucleotide Polymorphisms (SNPs) in VEGF Pathway Genes With Progression-free Survival (PFS) and Blood Pressure (BP) in Metastatic Renal Cell Carcinoma (mRCC) in the Phase 3 Trial of Axitinib Versus Sorafenib (AXIS Trial)

R. Motzer, B. Rini, B. Escudier, 2011 .

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors

R. Figlin, R. Motzer, R. Bukowski, 2007 .

O4 Tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from the Phase III randomized, open-label, multicenter TIVO-1 trial

R. Motzer, A. Berkenblit, C. Sternberg, 2012 .

KEYNOTE-427 cohort A: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC).

J. Larkin, M. Atkins, V. Matveev, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

1448O Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) + lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)

L. Lacombe, C. Gedye, P. Tomczak, 2022, Annals of Oncology.

Cabozantinib for the treatment of renal cell carcinoma patients

C. Szczylik, P. Potemski, P. Tomczak, 2017 .

Efficacy and safety data from patients with advanced renal cell cancer treated with tivozanib hydrochloride after progression on sorafenib.

A. Berkenblit, A. Strahs, P. Tomczak, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: Final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902).

C. Sternberg, P. Tomczak, Thomas E. Hutson, 2015 .

Safety and efficacy of AMG 386 in combination with sunitinib in patients with metastatic renal cell carcinoma (mRCC) in an open-label multicenter phase II study.

A. Ravaud, M. Atkins, P. Tomczak, 2012 .

The quality of life improvement in patients administered cytotoxic drugs as the result of new supportive methods of therapy application

R. Ramlau, P. Tomczak, M. Litwiniuk, 1996 .

Adjuvant pembrolizumab (pembro) for renal cell carcinoma (RCC) across UCLA Integrated Staging System (UISS) risk groups and disease stage: Subgroup analyses from the KEYNOTE-564 study.

T. Choueiri, S. Park, P. Tomczak, 2023, Journal of Clinical Oncology.

7141 POSTER Phase II Trial of the Oral Multikinase Inhibitor Regorafenib (BAY 73-4506) as First-line Therapy in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)

T. Eisen, H. Joensuu, P. Nathan, 2011 .

7105 Phase II trial of the oral multikinase inhibitor BAY 73–4506 as 1st-line therapy in patients with metastatic or unresectable renal cell cancer (RCC)

T. Eisen, H. Joensuu, P. Nathan, 2009 .

Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.

M. Climent, L. Lacombe, Chung-Han Lee, 2023, The Lancet Oncology.

First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B

M. Climent, M. Atkins, Su-Jin Shin, 2019, Annals of Oncology.

[Religiousness of patients with diagnosis of schizophrenia. Wide-ranging studies].

P. Tomczak, 2006, Psychiatria Polska.

860 PHASE III RANDOMIZED TRIAL OF SUNITINIB MALATE VERSUS INTERFERON-ALFA AS FIRST-LINE SYSTEMIC THERAPY FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

R. Figlin, R. Motzer, M. Michaelson, 2007 .

Efficacy of cabozantinib (C) vs everolimus (E) in patients (pts) with advanced renal cell carcinoma (RCC) and bone metastases (mets) from the phase III METEOR study.

R. Motzer, T. Powles, T. Choueiri, 2016 .

Final Overall Survival (OS) Results from the Randomised, Double-Blind, Placebo-Controlled, Phase III AVADO Study of Bevacizumab (BV) Plus Docetaxel (D) Compared with Placebo (PL) Plus D for the First-Line Treatment of Locally Recurrent (LR) or Metastatic Breast Cancer (mBC).

N. Harbeck, D. Miles, L. Dirix, 2009 .

Changes in central and peripheral blood pressure parameters during antiangiogenic treatment of metastatic renal cell carcinoma.

R. Ramlau, P. Tomczak, A. Tykarski, 2019, Polish archives of internal medicine.

Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial

T. Powles, T. Choueiri, M. Voss, 2023, The Lancet.

Commentary on "Comparative effectiveness of axitinib vs. sorafenib in advanced renal cell carcinoma (AXIS): A randomized phase

D. Cella, C. Szczylik, B. Escudier, 2012 .

Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

R. Amato, C. Szczylik, P. Tomczak, 2010, Clinical Cancer Research.

Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial.

R. Motzer, A. Berkenblit, C. Sternberg, 2012 .

Abstract P2-16-04: Plasma Biomarker Analyses in the AVADO Phase III Randomized Study of First-Line Bevacizumab + Docetaxel in Patients with Human Epidermal Growth Factor Receptor (HER) 2-Negative Metastatic Breast Cancer

D. Miles, L. Dirix, X. Pivot, 2010 .

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

R. Figlin, R. Motzer, M. Michaelson, 2007, The New England journal of medicine.